Login to Your Account

Esperion partner-shopping after wins, target NDA time moved up

By Randy Osborne
Staff Writer

Tuesday, August 8, 2017

As Wall Street hailed Esperion Therapeutics Inc.'s phase II win with its triplet pill to lower cholesterol, the company moved up by three months the filing target for NDAs related to the program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription